Large Degree of Innovation in
NSCLC Pipeline
The NSCLC pipeline currently has
389 products in active development across all stages, but a stark contrast between
the mechanisms of action employed in the current market and the pipeline is
evident. Where the market comprises primarily ineffective chemotherapies that
target tubulin or DNA replication, the pipeline shows an incredibly diverse
range of therapies targeting multiple signaling pathways and molecules integral
to cancer development. This diversity is partially due to the presence of 122
first-in-class products, which accounts for 38% of the overall pipeline
therapies that disclosed their target. In an industry, market and development
landscape that favors first-in-class over non-first-in-class development in
many ways, such as through faster approval or greater revenue, this finding has
strategic implications for a wide array of market participants, both large and
small. Despite a high attrition rate in NSCLC, first-in-class therapies that
reach the market have the potential to transform and improve the NSCLC
treatment landscape.
Read
Complete Report with TOC @ http://www.radiantinsights.com/research/frontier-pharma-non-small-cell-lung-cancer-identifying-and-commercializing-first-in-class-innovation
Alignment of First-in-Class
Molecular Target with Disease Causation
The method of characterizing
NSCLC tumors is currently shifting from the traditional histology-based
characterization to a more specific molecule-based method of characterization.
This has resulted in the identification of key oncogenic mutations in NSCLC and
has coincided with the rise of targeted pipeline therapies, which are designed
to target proteins in signaling pathways that are frequently mutated, amplified
or overexpressed in NSCLC. Aligning the molecular target with disease-causing
signaling pathways and frequently mutated pathways therapies can benefit from
reduced systemic cytotoxic effects while still inhibiting tumor-promoting
signaling. Therefore, targeted therapies often display superior safety and
efficacy to chemotherapies.
About Radiant
Insights
Radiant
Insights is a platform for companies looking to meet their market research and
business intelligence requirements. We assist and facilitate organizations and
individuals procure market research reports, helping them in the decision
making process. We have a comprehensive collection of reports, covering over 40
key industries and a host of micro markets. In addition to over extensive
database of reports, our experienced research coordinators also offer a host of
ancillary services such as, research partnerships/ tie-ups and customized
research solutions.
Contact:
Michelle
Thoras
Corporate
Sales Specialist, USA
Radiant
Insights, Inc
Phone:
1-415-349-0054
Toll
Free: 1-888-202-9519
Blog
URL: http://chemicalmaterialsmarket.blogspot.in/
No comments:
Post a Comment